Mahmoud Aljurf

Aug 1, 2024 | nature.com | Myriam Labopin |Depei Wu |Mahmoud Aljurf |Edouard Forcade |Jakob Passweg |Thomas Pabst | +7 more

AbstractCore-binding factor acute myeloid leukemia (CBF-AML) represents 12–15% of all AML cases. Although CBF positivity infers a survival advantage, overall survival (OS) remains dismal. Treatment is with cytarabine/anthracycline-based chemotherapy induction followed by high-dose cytarabine (HiDAC) consolidation. Allogeneic hematopoietic stem cell transplantation (allo-SCT) is reserved for relapse or for patients having not achieved MRD-negativity at high risk for relapse.

Jan 3, 2024 | thelancet.com | Olaf Penack |Humboldt-Universität zu Berlin |Monia Marchetti |Mahmoud Aljurf

1. Penack O Marchetti M Ruutu T et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020; 7: e157-e1672. Byrne M Mattison R Bercovitz R et al. Identifying experts for clinical practice guidelines: perspectives from the ASH Guideline Oversight Subcommittee. Blood Adv. 2023; 7: 4323-43263.

Dec 12, 2023 | nature.com | Xavier Poiré |Myriam Labopin |Gerard Socie |Edouard Forcade |Yves Chalandon |Mahmoud Aljurf | +3 more

AbstractAllogeneic hematopoietic cell transplantation (allo-HCT) remains the best consolidation strategy for acute myeloid leukemia (AML) with complex karyotype (CK). However, CK is a heterogenous and highly diverse entity. Numerical abnormalities have been associated with a controversial prognosis and AML with only multiple numerical abnormalities known as pure hyperdiploid karyotype (HDK) may have a distinct prognosis after allo-HCT compared to non-pure HDK CK AML.

Mar 23, 2023 | nature.com | Mahmoud Aljurf

AbstractPGF is a devastating complication after allogeneic transplant. We retrospectively analyzed our haploidentical transplant registry to report the incidence and impact of DSA and anti-HLA on engraftment. 107 patients were identified. Median recipient-age of 22, median donor-age of 31. Sixty-two patients had AML (58%), 29 had ALL (27%), 16 (15%) had other malignancies.